DiaKine Therapeutics and Kinexum Metabolics to Develop Combination Treatment to Type 1 Diabetes
News May 07, 2008
DiaKine Therapeutics, Inc. and Kinexum Metabolics, Inc. have announced an agreement to jointly develop a new combination therapy that has shown, in preclinical studies, to cause type 1 diabetes to go into remission by protecting and promoting the growth of new insulin-producing cells.
A Phase 2 human clinical trial with the new combination therapy, consisting of DiaKine’s Lisofylline (LSF) and Kinexum’s INGAP peptide, is expected to begin in late 2008. The trial will be unique in that patients who are beyond the ‘newly diagnosed’ period will be included in the study. Current trials seeking to treat people with type 1 diabetes do not include those with established disease.
“We believe these two drugs in combination create a unique and highly-effective treatment that could restore endogenous insulin to people with type 1 diabetes,” said Dr. Jerry Nadler, Chief Scientific Office for DiaKine Therapeutics. “It is becoming abundantly clear that a combination therapy is the best path for restoring the body’s natural ability to regulate blood sugar and giving people with type 1 diabetes their lives back.”
“Pursuing a cure for type 1 diabetes remains the strongest interest and commitment in my career. I see great promise in this scientific and corporate collaboration for achieving a definitive treatment of this difficult disease,” said Alexander “Zan” Fleming, M.D., who headed diabetes drug review at FDA and now serves as Chief Medical Officer of Kinexum Metabolics.
“We believe that the combination therapy of Lisofylline and INGAP peptide has the potential to be a blockbuster drug,” said Keith D. Ignotz, President and CEO of DiaKine Therapeutics. “We believe that, if successful, this new therapy could dramatically change the approach to treating diabetes.” Kevin Roché, CEO of Kinexum Metabolics, added, “It is clear that we will not get to a cure for type 1 diabetes if we don’t use a combination of therapies. This collaboration is part of the plan for doing that sooner than later.”
Lisofylline is said to be a synthetic small molecule with novel anti-inflammatory properties. LSF has demonstrated that it can prevent Type-1 diabetes in preclinical models. LSF has shown to improve cellular mitochondrial function and to reduce interleukin 12 (IL-12) signaling and STAT-4 activation in target cells and tissues. IL-12 and STAT 4 activation are important pathways linked to inflammation and immune damage to insulin producing cells.
Islet neogenesis associated protein (INGAP) is a member of the Reg3 family of pancreatic proteins. INGAP peptide, the active portion of the larger protein, induces islet regeneration in multiple species including humans. It is currently under development by Kinexum Metabolics, Inc.
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Comments | 0 ADD COMMENT
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
World Congress on Plant Science and Molecular Biology
Sep 12 - Sep 13, 2018